Cargando…
Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward
Perioperative therapy for non-small cell lung cancer has been studied extensively in a bid to improve overall survival, as approximately half of the patients with surgically resectable tumors at the time of diagnosis relapse. In recent years, immune checkpoint inhibitor therapies, such as the anti-p...
Autores principales: | Shinada, Kanako, Murakami, Shuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939665/ https://www.ncbi.nlm.nih.gov/pubmed/36814961 http://dx.doi.org/10.2147/OTT.S399657 |
Ejemplares similares
-
Lupus Nephritis: Current Perspectives and Moving Forward
por: Lichtnekert, Julia, et al.
Publicado: (2022) -
Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review
por: Maeda, Chihiro, et al.
Publicado: (2023) -
PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016) -
Current issues and perspectives in PD-1 blockade cancer immunotherapy
por: Chamoto, Kenji, et al.
Publicado: (2020) -
PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions
por: Xia, Liliang, et al.
Publicado: (2019)